CHOSA Oncology AB's abstract Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer accepted at 2023 ASCO Annual Meeting
CHOSA Oncology a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that an abstract with the title ‘Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer’ has been accepted for a poster presentation at the world’s biggest and prestigious cancer conference American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023 in Chicago, USA.
CEO Peter Buhl will present the data at the ASCO meeting taking place June 2-6 online and in person at the McCormick Place in Chicago. The poster shows the final data from a phase 2 study evaluating the ability of the DRP® companion diagnostic for cisplatin to prospectively identify patients with metastatic breast cancer that are likely to respond to treatment with LiPlaCis®, a targeted liposomal formulation of cisplatin. The study was conducted in collaboration with investigators at hospitals in Denmark. CHOSA Oncology has inlicensed worldwide rights to the LiPlaCis program and its DRP which together is named iCIP™.
The poster presentation details are as follows:
Poster Title: “Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.”
Authors: Nielsen, D., Jakobsen, E,H., Langkjer, S.T., Danoe, H., Balslev, E., Knoop, A., … Lassen, U.N.
Abstract Number: 3130
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date and Time: 6/3/2023, 8:00 AM-11:00 AM local time
This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-04-2023 13:00 CET.
For additional information contact:
Peter Buhl Jensen, CEO
pbj@buhloncology.com
+ 45 21 60 89 22
CHOSA in short
CHOSA Oncology AB is an oncology biotechnology company led by a proven international team with specialists in oncology, drug development, running clinical trials, regulatory expertise, and business development. CHOSA intends to enter into agreements for partnership or sublicensing of iCIP™.
About iCIP™
CHOSA is focused on late-stage clinical development of iCIP™ (LiPlaCis® and its DRP® companion diagnostic together) to which it has worldwide rights. The cisplatin DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin.
In essence, iCIP™ combines the identification of patients that will benefit from cisplatin treatment with the ability to treat them with higher efficacy and less toxicity. We have strong phase 2b data in metastatic breast cancer, demonstrating that patients selected by DRP® responded better to treatment; have longer progression-free survival; and maybe even an overall longer total survival than those patients who were identified as unlikely to respond well to the treatment. The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Cisplatin therapy after surgery is a gold standard that clearly increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin and who should have something else. This is where the cisplatin DRP is a potential game changer. Cisplatin DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to kill remaining tumor cells. Thus, patients with the 10% highest scores had a 3-year survival of 90% whereas the patients with the lowest 10% score had much lower survival with only 40% surviving 3 years1.
1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609
DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA.
LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.